Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The Congress Scientific Watch provides ESMO Members with fresh comments and analysis from selected abstracts presented during major international Oncology meetings.
Login to start reading, or Join ESMO - All articles are Open Access after 6 months.
Archive for articles from 2022.
From the 2023 AACR Annual Meeting:
Patients with gliomas, gynaecological tumours and pancreatic cancer could benefit from treatment with pemigatinib if they harbour an FGFR mutation
From the 2023 AACR Annual Meeting:
Some children and adolescents with solid tumours harbouring gene alterations may benefit from a combination of olaparib plus ceralasertib
From the 2023 AACR Annual Meeting:
Preliminary results suggest REGN5459 has efficacy as a treatment for patients with heavily pretreated multiple myeloma
From the 2023 AACR Annual Meeting:
Patients with advanced desmoplastic melanoma have achieved a high objective response rate to pembrolizumab monotherapy
From ELCC 2023:
Post-hoc exploratory findings suggest that four cycles of chemotherapy followed by tremelimumab and durvalumab may optimise tumour shrinkage for metastatic non-small-cell lung cancer
From ELCC 2023:
HLA-I expression in non-small-cell lung cancer may help predict response to immunotherapy
From ELCC 2023:
Patients undergoing resection of stage IB–III non-small-cell lung cancer may derive a survival benefit from use of both neoadjuvant and adjuvant atezolizumab
From ELCC 2023:
Liposomal irinotecan does not offer significantly better overall survival than topotecan for patients with small-cell lung cancer that has progressed during or after first-line platinum-based chemotherapy
From ELCC 2023:
APPLE and NORTHSTAR updates add to understanding of osimertinib use among patients with advanced EGFR-mutated non-small-cell lung cancer
From 2023 ASCO GU Cancers Symposium:
The KEYNOTE-057 trial has shown promising efficacy and safety of pembrolizumab monotherapy for BCG-unresponsive, papillary high-risk non-muscle-invasive bladder cancer
From 2023 ASCO GU Cancers Symposium:
Patients with platinum-ineligible metastatic urothelial cancer that has progressed on immune checkpoint therapy could benefit from treatment with the antibody–drug conjugate sacituzumab govitecan
From 2023 ASCO GU Cancers Symposium:
Phase IIa data point to the potential of combining the first-in-class innate immune activator BXCL701 with pembrolizumab in men with refractory small-cell neuroendocrine cancer of the prostate
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
